Sunday , October 20 2019

Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.

Home / Therapies / GLP-1 Agonist Therapy Center

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

EXCEED Trial: Efpeglenatide Displays Significant Reduction in HbA1c and Body Weight

6 days ago Type 2 Diabetes, GLP-1 Agonist Therapy Center

Efpeglenatide, a new GLP-1 receptor agonist, referenced to liraglutide in Phase II trial.

Oral Semaglutide – A Phase 3 Trial in Patients with Type 2 Diabetes

4 weeks ago Type 2 Diabetes, Paid, GLP-1 Agonist Therapy Center

Final results from a phase 3 study preceded FDA approval of oral semaglutide.

Liraglutide Linked to Gallbladder Complications

4 weeks ago Type 2 Diabetes, GLP-1 Agonist Therapy Center

A secondary analysis of the LEADER trial to investigate the safety of liraglutide in patients with type 2 diabetes.

Phase 3 Comparison Trial: GLP-1 vs DPP-4

Sep 17, 2019 Type 2 Diabetes, DPP-4 Therapy Center, GLP-1 Agonist Therapy Center

A recent study demonstrates the efficacy of a new, once daily oral option for patients with type 2 diabetes already on metformin.

Exenatide Reduces Risk of MACE for Type 2 Diabetes Patients

Sep 10, 2019 Cardiology, GLP-1 Agonist Therapy Center

Exenatide joins trend of GLP-1 agonists showing benefit for patients with established CVD.

Liraglutide and Sitagliptin Useful for Nonalcoholic Fatty Liver Disease in T2DM

Aug 20, 2019 Type 2 Diabetes, DPP-4 Therapy Center, GLP-1 Agonist Therapy Center

A recent study reveals Liraglutide and Sitagliptin reduce intrahepatic lipid in patients with T2DM and IHL.

CV Benefit of GLP-1 Agonists and SGLT2 Inhibitors Misleading for Black Patients? ADA

Jul 13, 2019 Cardiology, GLP-1 Agonist Therapy Center, SGLT-2 Therapy Center

Claims of improved cardiovascular outcomes from GLP-1 agonists and SGLT2 inhibitors not proven significant for black patients.

PIONEER 5 Study Validates Oral GLP-1 Effectiveness

Jul 9, 2019 Type 2 Diabetes, Nephrology, GLP-1 Agonist Therapy Center

The PIONEER 5 study discusses the safety and efficacy of the first oral GLP-1 receptor agonist, a potential substitute to injections.

Cardiovascular Benefits of Oral GLP-1RA in High-Risk Patients with Type 2 Diabetes

Jul 6, 2019 Cardiology, GLP-1 Agonist Therapy Center

Results from the recently published PIONEER trial series demonstrate the overall diabetic benefits of oral semaglutide, a novel GLP-1 receptor agonist.

Liraglutide for Youth with Type 2 Diabetes

Jun 29, 2019 Type 2 Diabetes, Pediatrics, GLP-1 Agonist Therapy Center

The lack of studies for children and adolescents with type 2 diabetes has led to an absence of approval of new drugs for this patient population. This study reports findings of Liraglutide for youth.

Page 1 of 1512 3 4 5 » 10...Last »